On May 28, GenScript Biotech fell 5.01% in regular trading, trading at HKD 14.39/share, with trading volume of HKD 101 million.

On the news front, the stock had surged over 5% in the prior session after its associate company Legend Biotech announced multiple research results at the ASCO annual meeting, including Phase 1 clinical data for LB2102, a DLL3-targeting CAR-T therapy for relapsed or refractory small cell lung cancer, along with new CARVYKTI data. The current decline appears driven by profit-taking following the prior session's rally on the ASCO catalyst.

Additionally, Hong Kong Stock Connect channels had seen consecutive days of significant net outflows prior to this session, raising market concerns over institutional selling into the strength. Within the Life Sciences Tools & Services sector, broad weakness prevailed, with Wuxi AppTec down 3.2%, Wuxi Biologics down 3.68%, Wuxi XDC down 5.85%, and Insilico down 3.49%, further pressuring sentiment across the space.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)